Pre-existing Fc profiles shape the evolution of neutralizing antibody breadth following influenza vaccination.
FCGR2B
Fc receptor
antibody
hemagglutination inhibition
influenza
vaccine
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
21 03 2023
21 03 2023
Historique:
received:
07
02
2022
revised:
08
12
2022
accepted:
19
02
2023
pubmed:
16
3
2023
medline:
25
3
2023
entrez:
15
3
2023
Statut:
ppublish
Résumé
Under the ever-present threat of a pandemic influenza strain, the evolution of a broadly reactive, neutralizing, functional, humoral immune response may hold the key to protection against both circulating and emerging influenza strains. We apply a systems approach to profile hemagglutinin- and neuraminidase-specific humoral signatures that track with the evolution of broad immunity in a cohort of vaccinated individuals and validate these findings in a second longitudinal cohort. Multivariate analysis reveals the presence of a unique pre-existing Fcγ-receptor-binding antibody profile in individuals that evolved broadly reactive hemagglutination inhibition activity (HAI), marked by the presence of elevated levels of pre-existing FCGR2B-binding antibodies. Moreover, vaccination with FCGR2B-binding antibody-opsonized influenza results in enhanced antibody titers and HAI activity in a murine model. Together, these data suggest that pre-existing FCGR2B binding antibodies are a key correlate of the evolution of broadly protective influenza-specific antibodies, providing insight for the design of next-generation influenza vaccines.
Identifiants
pubmed: 36921600
pii: S2666-3791(23)00081-2
doi: 10.1016/j.xcrm.2023.100975
pmc: PMC10040413
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Influenza Vaccines
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100975Subventions
Organisme : NIAID NIH HHS
ID : R01 AI153098
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007245
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI080289
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI146785
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI137057
Pays : United States
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests G.A. is an equity holder in Seromyx Systems and Leyden Labs and is an employee of Moderna. C.M.B. is an employee and equity holder of Leyden Labs. S.M., S.S., and H.K. were/are employees of Sanofi Pasteur, Inc.
Références
Nat Med. 2018 Oct;24(10):1590-1598
pubmed: 30177821
J Infect Dis. 2011 Dec 15;204(12):1879-85
pubmed: 21998477
Mol Immunol. 2008 Sep;45(15):3926-33
pubmed: 18691763
Cell. 2015 May 21;161(5):1035-1045
pubmed: 25976835
Nature. 2020 Dec;588(7838):485-490
pubmed: 33032297
Immunity. 2013 Jun 27;38(6):1164-75
pubmed: 23770227
Science. 2015 Sep 18;349(6254):1301-6
pubmed: 26303961
J Infect Dis. 2018 Jul 2;218(3):347-354
pubmed: 29506129
N Engl J Med. 2014 Aug 14;371(7):635-45
pubmed: 25119609
Mol Syst Biol. 2019 May 2;15(5):e8747
pubmed: 31048360
Sci Rep. 2017 Jan 18;7:40027
pubmed: 28098157
Immunol Rev. 2015 Nov;268(1):25-51
pubmed: 26497511
Nat Commun. 2016 Sep 13;7:12780
pubmed: 27619409
Sci Transl Med. 2020 Dec 9;12(573):
pubmed: 33298562
Nat Med. 2021 Jan;27(1):106-114
pubmed: 33288923
Sci Immunol. 2018 Aug 17;3(26):
pubmed: 30120121
J Vis Exp. 2013 Nov 06;(81):e51112
pubmed: 24300384
Science. 2012 Sep 14;337(6100):1343-8
pubmed: 22878502
Rheumatology (Oxford). 2016 May;55(5):939-48
pubmed: 26748351
Curr Opin Virol. 2011 Oct;1(4):254-62
pubmed: 22125588
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
Nature. 2021 Jun;594(7862):253-258
pubmed: 33873199
J Virol. 2013 May;87(10):5468-76
pubmed: 23468489
Vaccines (Basel). 2018 Jun 29;6(3):
pubmed: 29966222
Nature. 1996 Jan 25;379(6563):346-9
pubmed: 8552190
Curr Protoc Microbiol. 2013;Chapter 15:15G.1.1-15G.1.24
pubmed: 23686827
NPJ Vaccines. 2019 Feb 11;4:9
pubmed: 30775000
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11931-11936
pubmed: 27698132
Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):E5944-E5951
pubmed: 27647907
Nat Med. 2016 Dec;22(12):1456-1464
pubmed: 27820605
PLoS One. 2017 Nov 1;12(11):e0185666
pubmed: 29091724
J Clin Microbiol. 2010 Mar;48(3):928-40
pubmed: 20089763
mBio. 2018 Apr 3;9(2):
pubmed: 29615508
J Immunol. 1981 Jan;126(1):127-30
pubmed: 7451963
Vaccines (Basel). 2020 Aug 21;8(3):
pubmed: 32825605
Blood. 2012 Jun 14;119(24):5640-9
pubmed: 22535666
mBio. 2016 Oct 4;7(5):
pubmed: 27703076
J Virol. 2008 Nov;82(21):10493-501
pubmed: 18715929
J Immunol. 2012 Oct 1;189(7):3430-8
pubmed: 22956577
Immunity. 2021 Apr 13;54(4):815-828.e5
pubmed: 33852832
J Exp Med. 2008 Apr 14;205(4):883-95
pubmed: 18362174
J Hyg (Lond). 1972 Dec;70(4):767-77
pubmed: 4509641
J Immunol. 1995 Aug 1;155(3):1165-74
pubmed: 7543517
PLoS One. 2011 Mar 23;6(3):e17223
pubmed: 21448268
J Immunol Methods. 2019 Aug;471:46-56
pubmed: 31132351
Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5
pubmed: 30092199
MAbs. 2017 Jul;9(5):767-773
pubmed: 28463043
Nat Rev Immunol. 2010 May;10(5):328-43
pubmed: 20414206
J Exp Med. 1989 Oct 1;170(4):1369-85
pubmed: 2529342
J Immunol. 2014 Apr 1;192(7):3021-8
pubmed: 24563255
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7881-5
pubmed: 20385827
Pharmaceutics. 2021 Jan 07;13(1):
pubmed: 33430259
J Virol. 2015 Mar;89(6):3308-17
pubmed: 25589639
MAbs. 2010 Mar-Apr;2(2):181-9
pubmed: 20150767
Clin Exp Immunol. 1981 Feb;43(2):231-9
pubmed: 6974064
Nat Rev Immunol. 2019 Jun;19(6):383-397
pubmed: 30837674
Virus Res. 2004 Jul;103(1-2):133-8
pubmed: 15163501
Immunology. 1979 May;37(1):69-76
pubmed: 468304
PLoS Pathog. 2016 Jun 23;12(6):e1005692
pubmed: 27336297
J Immunol Methods. 2019 Oct;473:112630
pubmed: 31301278
Cell. 2015 Jul 2;162(1):160-9
pubmed: 26140596
Sci Transl Med. 2014 Mar 19;6(228):228ra38
pubmed: 24648341
PLoS One. 2011 Mar 09;6(3):e17377
pubmed: 21408070
mBio. 2022 Aug 30;13(4):e0157722
pubmed: 35762593
Vaccines (Basel). 2013 Aug 09;1(3):328-42
pubmed: 26344116